Acetaminophen (N-acetyl-p-aminophenol, APAP) is one of the most widely used over-the-counter antipyretic analgesic medications. Despite being safe at therapeutic doses, an accidental or intentional overdose can result in severe hepatotoxicity; a leading cause of drug-induced liver failure in the U.S. Depletion of glutathione (GSH) is implicated as an initiating event in APAP-induced toxicity. N-acetylcysteine (NAC), a GSH precursor, is the only currently approved antidote for an APAP overdose. Unfortunately, fairly high doses and longer treatment times are required due to its poor bioavailability. In addition, oral and intravenous administration of NAC in a hospital setting are laborious and costly. Therefore, we studied the protective effects of N-acetylcysteineamide (NACA), a novel antioxidant, with higher bioavailability and compared it with NAC in APAP-induced hepatotoxicity in a human-relevant in vitro system, HepaRG. Our results indicated that exposure of HepaRG cells to APAP resulted in GSH depletion, reactive oxygen species (ROS) formation, increased lipid peroxidation, mitochondrial dysfunction (assessed by JC-1 fluorescence), and lactate dehydrogenase release. Both NAC and NACA protected against APAP-induced hepatotoxicity by restoring GSH levels, scavenging ROS, inhibiting lipid peroxidation, and preserving mitochondrial membrane potential. However, NACA was better than NAC at combating oxidative stress and protecting against APAP-induced damage. The higher efficiency of NACA in protecting cells against APAP-induced toxicity suggests that NACA can be developed into a promising therapeutic option for treatment of an APAP overdose.
Introduction
Overdose of acetaminophen (APAP), an effective antipyretic/analgesic medication, is a common cause of acute liver failure in the U.S. [1] [2] [3] [4] Overdoses of APAP account for nearly 50-80,000 hospital emergency visits and about 500 deaths each year in the U.S. 5, 6 At therapeutic doses, more than 90% of the APAP is glucuronidated or sulfated in the liver and then excreted; 7, 8 however, about 4-5% is metabolized by cytochrome P450 enzymes (CYP450) (including CYP1A2, CYP3A4, and mainly CYP2E1) to the electrophilic intermediate N-acetyl-p-benzoquinoneimine (NAPQI). 7, 9 This intermediate is highly reactive and is eliminated by conjugation with glutathione (GSH) to directly form 3 -(glutathione-S-yl) acetaminophen, 7, 10 or catalyzed by glutathione S-transferase, which is excreted in urine. However, after an overdose of APAP, the formation of NAPQI exceeds the detoxification capacity of GSH so that it arylates essential nucleophilic macromolecules within the hepatocytes, forming stable APAP protein adducts. 11, 12 This represents an initial and irreversible step in the development of APAP-induced hepatotoxicity. 11 Since the detoxification of NAPQI by GSH is extremely rapid (k 1 ¼ 3.2 Â 10 4 M/s at pH 7.0), 13 covalent binding of NAPQI to proteins would occur only after more than 70% of the GSH is depleted. 14 NAPQI binds more frequently to mitochondrial protein 15, 16 that leads to mitochondrial membrane permeability transition (MPT). This is characterized by mitochondrial swelling, uncoupling of oxidative phosphorylation, and formation of pores in the mitochondrial membrane. 17 Consequently, the apoptosis-inducing factor and endonuclease G are released from the mitochondria and are translocated to the nucleus, resulting in fragmentation of DNA. 17 Collapse of the mitochondrial membrane potential, together with extensive DNA damage, contributes to necrosis of the hepatocytes. This is supported by studies which report that the prevention of MPT protected against APAP-induced damage. [18] [19] [20] Furthermore, the exposure of mouse hepatocytes to NAPQI stimulated the mitochondrial dysfunction that was observed with APAP. 21 Uncoupling of cytochrome P-450 2E1 appears to be a significant mechanism that leads to increased reactive oxygen species (ROS) in APAP toxicity. The superoxide anion, thus formed, dismutates to hydrogen peroxide 22 and eventually forms highly reactive hydroxyl radicals which may, in turn, oxidize lipids that lead to initiation of lipid peroxidation as well as oxidation of proteins and nucleic acids. In addition, GSH peroxidase, a major peroxide detoxification enzyme, is stalled due to the lack of its substrate, GSH. Thus, depletion of GSH, which is crucial for maintaining a cellular redox state, results in acute oxidative stress.
Since GSH depletion by excessive NAPQI is a critical event in APAP-induced hepatotoxicity, 23, 24 Nacetylcysteine (NAC), a GSH precursor that has been used to treat patients with APAP-induced toxicity, [25] [26] [27] is the only approved antidote for treatment of APAP-induced hepatotoxicity. NAC functions to restore GSH levels, the body's natural defense against endogenously generated ROS and NAPQI, by providing an important GSH precursor, cysteine, via deacetylation. 28, 29 Furthermore, treatment with excess NAC after APAP supplies mitochondrial energy substrates in the Krebs cycle and restores hepatic ATP levels. 30 Unfortunately, NAC is negatively charged at physiological pH, limiting its ability to cross cell membranes and, therefore, requires higher doses and longer treatment times. However, in NACA, a novel GSH-prodrug, the carboxyl group is replaced with an amide which increases its lipophilicity, allowing it to cross cell membranes.
NACA is an excellent source of sulfhydryl (-SH) groups that can be converted by the cells into metabolites capable of stimulating GSH synthesis. The molecule can also promote intracellular detoxification and act directly as a free radical scavenger. Previous studies have shown that NACA is lipophilic and can cross membranes, chelate Cu 2þ (which catalyzes free radical formation), scavenge free-radicals, and protect against oxidative stress. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] In addition, the nausea and vomiting, caused when NAC is administered orally, and the anaphylactic reactions that follow its intravenous administration, 41, 42 could be overcome by using a lower dose of NACA, which has higher bioavailability. Promising results with NACA in various oxidative stress-related disorders encouraged us to investigate the ability of NACA to protect against APAPinduced toxicity.
Therefore, the present study was undertaken to evaluate the therapeutic efficiency of NACA in APAP-induced toxicity. In addition, we used HepaRG, a human hepatoma cell line which expresses phases I and II drug metabolizing enzymes, membrane transporters, the GSH-related enzymes, and thioredoxin. Activities of phase I and II enzymes of this cell line were comparable to freshly isolated human hepatocytes. 43, 44 Previous studies have used HepG2, which is not an ideal model for studying drug metabolism and toxicity. HepG2 cells do not express phase I enzymes 45 and, therefore, cannot form the reactive metabolite, NAPQI, which initiates hepatotoxicity by depleting GSH and protein adduct formation. Moreover, the therapeutic efficiency of NACA was compared with NAC in APAP-induced toxicity in HepaRG cells.
Our data showed that NACA protects against APAPinduced toxicity by de novo synthesis of intracellular GSH, scavenging ROS, inhibiting lipid peroxidation, and preserving mitochondrial membrane potential. NACA is significantly better than NAC and can potentially be developed into a promising therapeutic option for patients undergoing therapy after an APAP overdose and also in hepatotoxicity resulting from long-term APAP use. The enhanced ability to penetrate cells allows NACA to be administered at a lower dose than NAC, giving the drug a greater therapeutic index and lowering the risk of side effects that traditionally have been associated with higher doses of NAC. 34 
Materials and methods

Materials
The human hepatoma cells (HepaRG) were obtained from Invitrogen. NACA was gifted by Dr Glenn Goldstein (David Pharmaceuticals, New York, NY). N-(1-pyrenyl)maleimide (NPM) was obtained from Sigma-Aldrich (St. Louis, MO). High performance liquid chromatography (HPLC) grade solvents were purchased from Fisher Scientific (Fair Lawn, NJ). All other chemicals were bought from Sigma-Aldrich (St. Louis, MO).
Culture of human hepatoma cells, HepaRG, and experimental design for oxidative stress parameters
The human hepatoma cells (HepaRG) were seeded in 75 cm 2 tissue culture flasks coated with type 1 rat tail collagen (Sigma-Aldrich, St. Louis, MO). They were maintained in William's E medium supplemented with 10% fetal calf serum, 100 U penicillin, 100 mg/mL streptomycin, 5 mg/mL insulin, and hydrocortisone in humidified 5% CO 2 /95% air at 37 C. The culture medium was renewed every 3 days. After about 2 weeks, when the flask was full, the cells were shifted to the same medium supplemented with 2% dimethyl sulfoxide (DMSO) (differentiation medium). The medium was renewed every 2-3 days for 2 more weeks. After that, the medium was switched to a DMSO-free medium for 1 day, and the cells were ready for experiments.
For dosing cells with APAP, NAC, and NACA, we used serum-free and growth-factor-free medium for all experiments, instead of the fully supplemented media described earlier. To assess the cytotoxicity of NAC/NACA, the HepaRG cells were incubated with different concentrations of NAC/NACA, ranging from 0.1 to 10 mM. NAC/NACA did not affect cell viability at concentrations lower than 500 mM. Cells were also incubated with different concentrations of APAP, ranging from 5 to 50 mM, to study its effect on cell viability. The cell viability decreased to approximately 60% of the control when treated with 20 mM of APAP and, therefore, this concentration of APAP was determined to be optimal for further studies. When cells were pretreated with different concentrations of NAC/NACA, followed by treatment with 20 mM of APAP, the optimum NAC/NACA dose that provided maximum protection was 250 mM NACA and, therefore, we chose to use 250 mM NAC/NACA for all other studies. Oxidative stress parameters, including GSH, MDA, and glutathione reductase (GR) activities were measured after the cells had been treated, as described here. After seeding the cells, the flasks were divided into the following six groups: (1) control, (2) NAC only, (3) NACA only, (4) APAP only, (5) APAP þ NAC, and (6) APAP þ NACA. In groups pretreated with NAC/NACA, a media containing 250 mM of NAC/ NACA were added and incubated for 2 h. After pretreatment, the media in the control, NAC only, and NACA-only groups were replaced with plain media, while the remaining three groups received media containing APAP for either 12 or 24 h. The cell pellets obtained were then further processed for appropriate assays. All assays were performed at least in triplicate.
Determination of cell viability
The HepaRG cells were seeded in a 96-well tissue culture plate, at a density of approximately 1.0 Â 10 4 cells/well, for a day. The medium was then discarded. The protective effects of NAC/NACA were studied by preincubating cells with 250 mM of NAC/NACA for 2 h, followed by treatment with 20 mM of APAP for 24 h in serum-free medium. After 24 h of APAP treatment, the medium was discarded and a Calcein AM assay KIT (Biotium, Inc. CA) was used to determine cell viability relative to the control group. The cells were washed three times with Phosphate buffered saline (PBS), and 100 mL of 2.0 mM Calcein AM in PBS were added to each well for 30 min at 37 C. The fluorescence was measured with an excitation wavelength at 485 nm and an emission wavelength of 530 nm, using a microplate reader (FLUOstar, BMG Labtechnologies, Durham, NC, USA). To further assess the role of NAPQI (a putative toxic metabolite of APAP) on cell viability, cells were pretreated with NAC/NACA, as described earlier, followed by incubation with 250 mM of NAPQI (dissolved in 0.1% DMSO) for 24 h. The media in the control groups also had 0.1% DMSO. After 24 h of APAP treatment, the medium was discarded and a Calcein AM assay KIT (Biotium, Inc. CA) was used to determine cell viability relative to the control group.
Lactate dehydrogenase release assay
Lactate dehydrogenase (LDH) measurement in the media determines the membrane integrity. HepaRG cells were seeded in the 96-well plate at a density of approximately 1 Â 10 4 cell/well and incubated with APAP for 24 h after appropriate pretreatment with NAC/NACA. We used the LDH assay kit (Promega), which quantitatively measures LDH, a stable cytosolic enzyme that is released upon cell lysis. The LDH that was released into the cultured medium was measured within 30 min by the coupled enzymatic assay.
Determination of intracellular GSH
Intracellular GSH content was determined by reverse phase HPLC, according to the method developed in our laboratory. 46 HepaRG cell samples were homogenized in serine borate buffer (SBB). Fifty microliters of this homogenate were added to 200 mL of HPLC grade water and 750 mL of NPM (1 mM in acetonitrile). The resulting solutions were incubated at room temperature for 5 min. The reaction was stopped by adding 10 mL of 2 N HCl. The samples were then filtered through a 0.45 mm filter (Advantec MFS, Inc. Dulin, CA, USA) and injected onto the HPLC system. A total of 5 mL of the sample was injected for analysis using a Thermo Finnigan TM Spectra SYSTEM SCM1000 Vacuum Membrane Degasser, Finnigan TM SpectraSYSTEM P2000 Gradient Pump, Finnigan TM SpectraSYSTEM AS3000 Autosampler, and FinniganTM SpectraSYSTEM FL3000 Fluorescence Detector (ex ¼ 330 nm and em ¼ 376 nm). The HPLC column was a Reliasil ODS-1 C18 column (Column Engineering, Ontario, CA, USA). The mobile phase was 70% acetonitrile and 30% water and was adjusted to a pH of 2.5 through the addition of 1 ml/L of both acetic and o-phosphoric acids. The NPM derivatives were eluted from the column isocratically at a flow rate of 1 mL/min.
Determination of total glutathione and glutathione disulfide (GSSG)
Total glutathione content was determined by reverse phase HPLC. HepaRG cells were homogenized in SBB. Twenty microliters of this homogenate were added to 60 mL of NADPH (2 mg/mL) in nanopure water and 20 mL of 1 unit/mL glutathione reductase were added to reduce GSSG. After 3 min of incubation at room temperature, the treated samples were diluted with 150 mL H 2 O, and then immediately derivatized with 750 mL of 1.0 mM NPM. These samples were analyzed as detailed for the determination of GSH using reverse phase HPLC. Data from the original GSH levels and the total GSH levels in each sample were subsequently used to calculate the levels of GSSG present in each sample.
Intracellular ROS measurement
Intracellular ROS generation was measured using a wellcharacterized probe, 2 0 ,7 0 -dichlorofluorescin diacetate (DCFH-DA). 47 HepaRG cells were seeded at a density of 1.25 Â 10 4 cells/well in a 96-well plate for a day. DCFH-DA was hydrolyzed by esterases to dichlorofluorescin (DCFH), which is trapped within the cell. This nonfluorescent molecule is then oxidized to fluorescent DCFH by the action of cellular oxidants. The cells were incubated with a solution of 40 mM DCFH-DA in phenol red free media for 1 h. This was followed by washing the cells twice with PBS. In the groups with NAC/NACA pretreatment, media containing 250 mM of NAC/NACA was added and incubated for 2 h. Once pretreated, the cells were washed twice with PBS and treated with 20 mM of APAP for 12 h. The fluorescence was determined at 485 nm excitation and 520 nm emission, using a microplate reader (FLUOstar, BMG Labtechnologies, Durham, NC, USA). 
Lipid peroxidation measurement
Malondialdehyde (MDA) is a thiobarbituric acid reactive substance. The extent of lipid peroxidation was determined as described by Shi et al. 48 Briefly, the cell pellets were homogenized in SBB. To 0.350 mL of cell homogenate, 0.550 mL of 5% trichloroacetic acid and 0.100 mL of 500 ppm butylated hydroxytoluene in methanol were added. The samples were then heated in a boiling water bath for 30 min. After cooling on ice, the samples were centrifuged. The supernatant fractions were mixed 1:1 with saturated thiobarbituric acid (TBA). The samples were again heated in a boiling water bath for 30 min. After cooling on ice, 0.50 mL of each sample was extracted with 1 mL of n-butanol and centrifuged to facilitate the separation phases. The resulting organic layers were first filtered through a 0.45 mm filter and transferred to a 96-well plate for analysis. Fluorescence was then measured (ex. 510 nm and em. 590 nm).
Determination of glutathione reductase (GR) activity
GR is the enzyme responsible for recycling GSSG into GSH via a reduction mechanism, utilizing both GSSG and NADPH as a substrate. The activity of this enzyme was determined using a commercial kit from OxisResearch (Portland, OR, USA). The oxidation of NADPH to NADP þ was accompanied by a decrease in absorbance at 340 nm, providing a spectrophotometric means for monitoring the enzyme activity of GR. The activity of GR in cells was determined by adding homogenate to a solution containing both GSSG and NADPH and then recording the absorbance as a function of time at 340 nm. The rate of decrease in the A340 was directly proportional to the GR activity in the sample.
Measurement of mitochondrial membrane potential (")m)
Mitochondrial membrane potential was determined using the potentiometric fluorescent dye JC-1 (Invitrogen). HepaRG cells were cultured in glass-bottom petri dishes and were treated with NAC/NACA and APAP as described earlier. The cells were washed twice with PBS and then incubated with JC-1 dye (1 mg/1 mL) in a medium for 30 min. The cells were then washed and placed under a fluorescence microscope in a phenolred-free medium. The stained cells were observed with an Olympus IX51 inverted microscope at 400 Â total magnification with a UPLFLN 60 Â NA 1.25 objective. FITC (ex 482/35 506DMem 536/40) and Texas red (ex 562/40 593DMem692/40) filters were used (Brightline). Images were captured with a Hamamatsu ORCA285 CCD camera. The shutters, filters, and camera were controlled using Slide Book software (Intelligent Imaging Innovations, Denver, CO, USA).
Determination of protein
Protein levels of the cell samples were measured by the Bradford method. 49 Bovine serum albumin was used as the protein standard.
Statistical analysis
All reported values were represented as the mean AE standard deviation (n ¼ 3-5). Statistical analysis was performed using the GraphPad Prism software (GraphPad, San Diego, CA). Statistical significance was ascertained by one-way as well as two-way analysis of variance, followed by Tukey's multiple comparison tests. Values of p < 0.05 were considered significant.
Results
Effect of APAP and NAC/NACA on HepaRG cell viability
A dose-and time-dependent decrease in cell viability was observed in HepaRG cells upon exposure to APAP (Figure  1(a) and (b)), which was confirmed using a Calcein AM assay. Based on the dose-response relationship, a 20 mM concentration of APAP, which decreased cell viability by about 40% in 24 h, was determined to be optimal for evaluating the protective effects of NAC/NACA. It is interesting that cell viability at 24 h was not significantly different from that at 12 h. To assess cytotoxicity of NAC/NACA, the HepaRG cells were incubated for 24 h with different concentrations of NACA or NAC (0.10, 0.50, 0.75, 1.0, 1.5, 5.0, and 10.0 mM). NACA was nontoxic below 1 mM; however, NAC induced toxicity in HepaRG cells above 0.75 mM (Figure 1(c) ).
Protective effect of NAC/NACA on APAP-induced cytotoxicity
To study the protective effects of NAC/NACA on APAPinduced toxicity, HepaRG cells were pretreated for 2 h with several concentrations of NAC or NACA, followed by incubation with 20 mM of APAP for 24 h. The cell viability was then measured using the Calcein AM Assay. There was a significant increase in the cell viability in the 250 mM NAC or NACA pretreatment group (Figure 2(a) ). Therefore, a 250 mM nontoxic dose of NAC/NACA was chosen for subsequent experiments to study their protective effects on APAP-induced cytotoxity and oxidative stress. Furthermore, when protective effects of NAC were compared with those of NACA at 250 mM, we observed that NACA offered significantly better protection than NAC. In addition to the Calcein AM assay, cytotoxicity was assessed by the extent of LDH released in the culture medium after APAP treatment. LDH release increased significantly after APAP treatment (to 370% of the control) after 24 h. NACA pretreatment significantly decreased it to 330% of the control (Figure 2(b) ), whereas NAC did not decrease it significantly compared with the APAP treatment group.
Protective effect of NAC/NACA on NAPQI-induced cytotoxicity
To substantiate the hypothesis that NAPQI, a toxic metabolite, was involved in the hepatotoxicity induced by APAP, cell viability was measured after directly treating HepaRG cells with NAPQI for 24 h. We chose 250 mM of NAPQI, based on the dose-response study (Figure 3(a) , which showed 40% cell death at this concentration, which was similar to 20 mM APAP. NACA pretreatment significantly increased it to 73% of the control (Figure 3(b) ). However, NAC pretreatment was not as effective at protecting cells against NAPQI-induced cytotoxicity.
Effect of NAC/NACA on intracellular levels of GSH, GSSG, and the ratio of GSH/GSSG To further support our hypothesis that depletion of intracellular GSH is a crucial event in APAP-induced toxicity, we investigated its effect on GSH at 12 h (Figure 4(a) ) and 24 h ( Figure 4(b) ). GSH levels significantly decreased to 48% of the control after treatment with 20 mM of APAP for 12 h. No significant increase in the GSSG levels was observed after APAP treatment in HepaRG cells for 12 h. However, the GSH/GSSG ratio, an important parameter of oxidative stress, decreased significantly in the 20 mM of APAP treatment group after 12 h. NACA pretreatment significantly increased the GSH level to 76% of the control in addition to increasing the ratio of GSH/GSSG to near control levels. Interestingly, 250 mM of NAC pretreatment was not effective at increasing the level of GSH and the GSH/GSSG ratio significantly after 12 h of APAP treatment (Figure 4(a) ). However, after 24 h of APAP treatment, both NAC and NACA were effective at increasing the GSH/GSSG ratio. Furthermore, NACA was significantly better than NAC at increasing intracellular GSH levels, decreasing the levels of GSSG and, thereby, increasing the ratio of GSH/GSSH after 24 h. 
Protective effect of NAC/NACA on APAP-induced increase in intracellular ROS
To elucidate the role of oxidative stress in APAP-induced toxicity, ROS levels were measured at several time points (1, 3, 6, 12, and 24 h) after treatment of HepaRG with 20 mM APAP. A significant time-dependent increase in ROS was observed upon treatment with APAP ( Figure 5(a) ). However, pretreatment with 250 mM NAC/NACA reduced it to near control levels ( Figure 5(b) ).
Protective effect of NAC/NACA on lipid peroxidation
MDA, an index of lipid peroxidation, was measured in HepaRG cells after treatment with APAP for 24 h. Significantly higher levels (592% of the control) of MDA were observed after 24 h, but not after 12 h of treatment (Table 1) . Pretreatment with 250 mM of NAC and NACA significantly reduced this increase in MDA to 302 and 263% of the control, respectively. Pretreatment with NACA (p < 0.05) was better than NAC (p < 0.0001) at decreasing lipid peroxidation, when compared to the control.
Effect of NAC/NACA on activity of GR in HepaRG cells treated with APAP
Although no significant change in GR activity was observed at 12 h, it significantly reduced to 28% of the control after 24 h of APAP treatment. NAC and NACA pretreatment significantly restored the GR activity to 57 and 70% of the control, respectively (Table 1) . NACA pretreatment was significantly better than NAC at restoring the activity of GR with p < 0.0001.
Effect of NAC/NACA on mitochondrial membrane potential in HepaRG cells treated with APAP
Mitochondrial dysfunction is a hallmark in APAPinduced hepatotoxicity. Disruptions in mitochondrial permeability and function were assessed by using the membrane-permeative potentiometric dye JC-1. This dye preferentially localizes to the mitochondria in healthy cells and forms aggregates which fluoresce red. However, in cells with mitochondrial dysfunction, where the mitochondrial membrane potential decreases, the dye diffuses into the cytoplasm and its monomeric form fluoresces green. As shown in Figure 6 , control cells were stained both red and green, whereas a decrease in red fluorescence was seen in the APAP-treated group. Decrease in the red fluorescence in the APAP-treated group indicated that APAP treatment suppressed Ém in the HepaRG cells. However, NAC/NACA pretreatment restored the mitochondrial membrane potential, as evidenced by red fluorescence similar to that of the control. These results support our hypothesis that NACA pretreatment preserves mitochondrial function in a manner similar to that of NAC.
Discussion
An overdose of APAP is one of the leading causes of death in the U.S. and accounts for huge hospitalization costs every year. Although only a few different mechanisms have been proposed for APAP-induced toxicity, a significant amount of evidence has pointed to the potential involvement of oxidative stress in APAP toxicity. [50] [51] [52] [53] [54] [55] [56] Depletion of GSH is one of the initiating steps in APAP-induced hepatotoxicity; 57 therefore, one strategy for restricting organ damage is to restore GSH levels by using GSH prodrugs. Since, NAC, the only approved antidote for APAP toxicity, has poor bioavailability and requires higher doses and longer treatment times, we studied the protective effect of NACA, which has higher bioavailability on APAP-induced hepatotoxicity and its effects were compared with those of NAC. Herein, we report the in vitro effects of APAP on the HepaRG cell line and the role of NACA in preventing APAP-induced hepatotoxicity, and these findings were compared with those of NAC.
Results from our study show that HepaRG cells treated with APAP experienced a significant decrease in GSH levels and cell viability, indicating that the increase in oxidative stress (which was due to the decrease in GSH levels) was responsible for reduced cell viability. A significant decrease in GSH levels after APAP treatment could be due to conjugation with NAPQI during the detoxification pathway. 57 Our results are in line with previous studies that reported a decrease in GSH levels upon APAP treatment in animal models and in cell cultures. 56, 58, 59, [60] [61] [62] [63] [64] [65] However, the time and amplitude of decreases varied with cell lines and the animal models used for these studies. In addition to a decrease in GSH, increases in intracellular GSSG have been reported during the recovery phase of cellular GSH content 50,66 after APAP treatment. Although, we did not see a significant increase in GSSG after 12 h of APAP treatment, we did see a significant increase in GSSG levels after 24 h of treatment with 20 mM APAP. Decreases in GSH with concomitant increases in GSSG, after APAP treatment, have been reported by Zhao et al. 67 Furthermore, the ratio of GSH/GSSG, which serves as a representative marker of the antioxidative capacity of a cell, decreased by about 2.6 -and 2.9-fold, respectively, after 12 and 24 h of APAP treatment. Our results are in accordance with a previous study that reported a similar decrease in the GSH/GSSG ratio after 24 h of APAP treatment. 68 APAP treatment significantly reduced cell viability in a concentration-and time-dependent manner. Our results are in agreement with previous studies that reported reduced cell viability after APAP treatment. 59, 67 To substantiate our hypothesis, that NAPQI formation is the main event in APAP-induced toxicity, we examined the effect of NAPQI exposure on cell viability. Exposure to NAPQI decreased cell viability in a dose-dependent fashion as well.
However, pretreatment with NACA significantly increased cell viability in the APAP/NAPQI-treated group (Figure 2) as well as the GSH levels (Figure 4 ) in the APAP treated group. This indicated that NACA had replenished the GSH levels in these cells and prevented oxidative stressinduced cell death. Although NAC was effective at increasing GSH levels, NACA was significantly better than NAC at increasing the GSH levels and the GSH/GSSG ratio, as well as cell viability after 24 h of treatment with APAP. This could be attributed to the lower bioavailability of NAC when compared with NACA.
The protective effects of NACA are probably mediated by its ability to supply cysteine for GSH biosynthesis, in addition to reducing extracellular cystine to cysteine, by conversion of GSSG to GSH by nonenzymatic thiol disulfide exchange, and by restoring GR activity. 34, 69 Despite being strong sulfhydryl nucleophiles, NAC/NACA are poor targets for NAPQI possibly due to their high pKa (9.6 for NAC) at physiological pH, which prevents the cysteine sulfhydryl group from converting into reactive anionic state. Studies have demonstrated that the protection of NAC against APAP overdose requires the synthesis of GSH. Indeed, previous research has suggested that NAC does not scavenge NAPQI and, therefore, cannot protect against the initial phase of toxicity. Rather, NAC hepatoprotection might involve an alternative mechanism that impacts the toxic phase, e.g. free radical trapping, increased GSH synthesis, or enhanced mitochondrial energy production. [70] [71] [72] [73] Further, depletion of GSH may lead to increased ROS in the cells. A significant, time-dependent increase in total ROS was observed in our study ( Figure 5(a) ). Our data are in agreement with other studies that have reported an increase in the production of ROS upon APAP treatment. 56, 62 In addition, Bajt et al. 56 showed that ROS was produced as a consequence of decreased GSH levels. However, pretreatment with NAC/NACA significantly decreased the ROS (Figure 5(b) ).
A decrease in GSH and an increase in ROS set off a cascade of further oxidative damage. ROS are capable of causing oxidative damage to all major macromolecules in cells, including lipids, proteins, and nucleic acids. Oxidized derivatives of these substrates were studied as markers of oxidative stress. Polyunsaturated fatty acids, major components of cell membranes, can undergo free radical attack and produce lipid peroxidation products that are frequently used to quantify oxidative stress-related injury. Levels of MDA, a lipid peroxidation by-product, provided a suitable index for measurement of lipid peroxidation in vivo. In accordance with previous studies, 60, 62, 65, 68, [74] [75] [76] we observed increased levels of MDA after 24 h of APAP treatment. In general, once toxic lipid peroxides are formed by free radicals, GPx attempts to eliminate them at the expense of GSH. Unavailability of GSH as a substrate for GPx might have stalled the process of lipid peroxide decomposition, thereby building up the levels of MDA. However, pretreatment with NAC/NACA was able to break the lipid peroxidation chain reaction by supplying an adequate amount of GSH, as a substrate for GPx, to effectively decompose lipid peroxides, thus reducing MDA levels. GR is a key antioxidant enzyme involved in the maintenance of cellular GSH homeostasis. It reduces GSSG back to the reduced form, GSH. A significant reduction in the activity of GR was observed upon APAP treatment. Decreased antioxidant enzyme activity upon APAP treatment has been reported in literature. 77 Decrease in GR activity, with time, has been reported in rat hepatocytes treated with 20 mM APAP. Some studies have indicated that loss of GSH will directly affect the activity of the GSH-dependent enzyme GR. Loss of protein sulfhydryl (protein-SH) groups, which are believed to be essential for enzyme activity under oxidative stress, has been previously reported. 78, 79 In addition, NAPQI is reported to cause loss in protein thiol groups. 80 Reduced activity of GR could also be attributed to a decrease in NADPH, a cofactor for GR, since NAPQI is reported to undergo rapid reduction to APAP using NADPH. 81 Under such circumstances, GSH is not regenerated, thus, leading to further oxidative stress. Decreased activity of GR seen in our experiments upon APAP treatment supports our hypothesis of GSH depletion as a key event in APAP-induced hepatotoxicity. Our results are in accordance with Al-Belooshi et al. 62 who reported a decrease in mitochondrial GR after APAP treatment.
Pretreatment with NACA increased the GR activity by 40%, which could have been due to regeneration of protein sulfhydryl groups by a nonenzymatic thiol-disulfide exchange. NACA was significantly better than NAC (p < 0.0001) at restoring GR activity.
Mitochondrial dysfunction is one of the key events in APAP-induced cell death. The MPT is recognized as an initiating phenomenon in APAP-induced toxicity. A decrease in the ÁÉm after APAP treatment was detected using fluorescence microscopy, which is consistent with disrupted mitochondrial function ( Figure 6 ). However, NAC/NACA pretreatment restored the mitochondrial membrane potential, as evidenced by a red fluorescence similar to that of the control. Studies by Nazareth et al. 82 showed a similar decrease in mitochondrial membrane potential after APAP treatment.
In summary, our data indicate that an APAP overdose causes oxidative stress and mitochondrial dysfunction in HepaRG cells. APAP-induced cell death in HepaRG cells could be due to depletion of GSH by NAPQI, which results in the formation of NAPQI-protein adduct and increased oxidative stress that leads to the loss of the mitochondrial membrane potential and, ultimately, cell death. Therefore, we conclude that NACA protects by synthesizing GSH which conjugates with NAPQI and prevents its subsequent binding to mitochondrial proteins and the resulting APAP-only Control APAP + NAC APAP + NACA Figure 6 Analysis of mitochondrial membrane potential (ÁÉm). ÁÉm was analyzed in the HepaRG cells after 24 h of APAP treatment, using the potential-dependent aggregate forming lipophilic cation JC-1. Mitochondria exhibited red fluorescence when ÁÉm was preserved. Mitochondria in APAP-treated cells showed a decrease in red fluorescence due to loss of ÁÉm. However, pretreatment with NAC/NACA preserved ÁÉm, as seen by red fluorescence similar to that of the control group. (A color version of this figure is available in the online journal.)
Tobwala et al. NACA protects against acetaminophen-induced oxidative stress 269 dysfunction. In addition, it protects by scavenging ROS and subsequent oxidative damage to macromolecules. These results suggested that NACA was significantly better than NAC at alleviating APAP-induced oxidative stress. Thus, NACA, a GSH prodrug with radical scavenging and antioxidant properties, appears to be a better therapeutic agent for treating APAP-induced toxicity and may require lower doses and treatment times. Based on these encouraging in vitro results, our future studies will focus on studying the protective effects of NACA in animal models. Further investigations will help determine NACA's efficacy in APAP-induced toxicities and an evaluation of the histology of livers in APAP-treated animals will provide additional information on NACA's therapeutic potential.
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